Meeting
2021 Genitourinary Cancers Symposium
Association of the neutrophil to eosinophil ratio with response to immunotherapy-based combinations in metastatic renal cell carcinoma.
Authors
Matthew D Tucker
Vanderbilt University Medical Center, Nashville, TN
Matthew D Tucker , Katy Beckermann , Kristin Kathleen Ancell , Kerry Schaffer , Renee McAlister , Deborah Wallace , Elizabeth Kaiser , Nancy B. Davis , W. Kimryn Rathmell , Brian I. Rini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 341)
DOI
10.1200/JCO.2021.39.6_suppl.341
Abstract #
341
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database.
First Author: Joseph Vento
Poster
2023 ASCO Annual Meeting
Association of neutrophil to eosinophil ratio (NER) with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line (1L) immune checkpoint inhibitors (ICI) –based regimens.
First Author: Marc Eid
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world clinical outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) in current immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) era.
First Author: Neil J. Shah
Poster
2022 ASCO Genitourinary Cancers Symposium
Association between on-treatment eosinophil dynamics and outcomes in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab.
First Author: Yu-Wei Chen